Pharma Mar Yönetim
Yönetim kriter kontrolleri 2/4
Pharma Mar CEO'su Jose Fernandez Sousa-Faro, Jan1986 tarihinde atandı, in görev süresi 40.33 yıldır. şirketin hisselerinin 6.43% doğrudan sahiptir ve bu hisselerin değeri € 111.10M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 15.2 yıl ve 3.9 yıldır.
Anahtar bilgiler
Jose Fernandez Sousa-Faro
İcra Kurulu Başkanı
n/a
Toplam tazminat
| CEO maaş yüzdesi | n/a |
| CEO görev süresi | 40.3yrs |
| CEO sahipliği | 6.4% |
| Yönetim ortalama görev süresi | 15.2yrs |
| Yönetim Kurulu ortalama görev süresi | 3.9yrs |
Son yönetim güncellemeleri
Recent updates
Pharma Mar's (BME:PHM) Solid Profits Have Weak Fundamentals
Despite posting some strong earnings, the market for Pharma Mar, S.A.'s ( BME:PHM ) stock hasn't moved much. We did...There May Be Underlying Issues With The Quality Of Pharma Mar's (BME:PHM) Earnings
Pharma Mar, S.A.'s ( BME:PHM ) robust earnings report didn't manage to move the market for its stock. We did some...Pharma Mar, S.A. (BME:PHM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Pharma Mar, S.A. ( BME:PHM ) last week reported its latest third-quarter results, which makes it a good time for...Is Pharma Mar (BME:PHM) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Risks To Shareholder Returns Are Elevated At These Prices For Pharma Mar, S.A. (BME:PHM)
It's not a stretch to say that Pharma Mar, S.A.'s ( BME:PHM ) price-to-sales (or "P/S") ratio of 7.4x right now seems...Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.80
Pharma Mar, S.A.'s ( BME:PHM ) dividend will be increasing from last year's payment of the same period to €0.80 on 27th...Pharma Mar (BME:PHM) Has Announced That It Will Be Increasing Its Dividend To €0.80
Pharma Mar, S.A. ( BME:PHM ) will increase its dividend from last year's comparable payment on the 27th of June to...
ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe
Successful approval of ZEPZELCA in Europe and new markets could significantly boost PharmaMar’s future revenues, leveraging positive trial results.We Think Shareholders Should Be Aware Of Some Factors Beyond Pharma Mar's (BME:PHM) Profit
The latest earnings release from Pharma Mar, S.A. ( BME:PHM ) disappointed investors. Our analysis found several...There's Reason For Concern Over Pharma Mar, S.A.'s (BME:PHM) Massive 27% Price Jump
The Pharma Mar, S.A. ( BME:PHM ) share price has done very well over the last month, posting an excellent gain of 27...Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%
Pharma Mar, S.A. ( BME:PHM ) shares have continued their recent momentum with a 55% gain in the last month alone. The...Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Pharma Mar, S.A. ( BME:PHM ) shares have continued their recent momentum with a 27% gain in the last month alone...Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65
Pharma Mar, S.A.'s ( BME:PHM ) dividend will be increasing from last year's payment of the same period to €0.65 on 14th...Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry
Pharma Mar, S.A. ( BME:PHM ) shareholders would be excited to see that the share price has had a great month, posting a...Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Last week, you might have seen that Pharma Mar, S.A. ( BME:PHM ) released its annual result to the market. The early...Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Pharma Mar fair value estimate is €52.37 Pharma Mar is...We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability
Pharma Mar, S.A.'s ( BME:PHM ) lackluster earnings announcement last week disappointed investors. We think that they...Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)
Market forces rained on the parade of Pharma Mar, S.A. ( BME:PHM ) shareholders today, when the analysts downgraded...Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued
Today we will run through one way of estimating the intrinsic value of Pharma Mar, S.A. ( BME:PHM ) by estimating the...CEO
Jose Fernandez Sousa-Faro
Mr. José María Fernández Sousa-Faro, Ph D., founded Pharma Mar, S.A.U. in 1986. He Founded Noscira, S.A., in 2000.He serves as the Chief Executive Officer and President of Pharma Mar, S.A.U. He serves as...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Founder | 40.3yrs | €294.00k | 6.43% € 111.1m | |
| Executive Vice-Chairman | no data | €124.00k | 0.00058% € 10.0k | |
| Founder | no data | Veri yok | Veri yok | |
| Chief Financial Officer | 26.3yrs | Veri yok | Veri yok | |
| Head of Capital Markets & Investor Relations | 11.3yrs | Veri yok | Veri yok | |
| General Counsel & Secretary of the Board of Directors | 6.7yrs | Veri yok | Veri yok | |
| Global Compliance Head | 6yrs | Veri yok | Veri yok | |
| Communication Director | no data | Veri yok | Veri yok | |
| Director of Corporate Development | 4.3yrs | Veri yok | Veri yok | |
| Director of Human Resources & IT | 22.8yrs | Veri yok | Veri yok | |
| Managing Director of Oncology & Virology Business Units | 19.1yrs | Veri yok | Veri yok | |
| Senior Vice President of Strategic Development | no data | Veri yok | Veri yok |
Deneyimli Yönetim: PHM 'un yönetim ekibi deneyimli ve deneyimlidir ( 15.2 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Founder | no data | €294.00k | 6.43% € 111.1m | |
| Executive Vice-Chairman | no data | €124.00k | 0.00058% € 10.0k | |
| Independent Other External Director | 5.3yrs | €35.00k | 0.062% € 1.1m | |
| Independent Other External Director | no data | €35.00k | Veri yok | |
| Proprietary Director | no data | €34.00k | 5.51% € 95.2m | |
| Independent Director | 7.3yrs | Veri yok | 0.010% € 179.1k | |
| Representative Proprietary Director | 5.4yrs | Veri yok | Veri yok | |
| Independent Director | 3.9yrs | Veri yok | 0.010% € 179.1k | |
| Independent Coordinating Director | 3.9yrs | Veri yok | Veri yok | |
| Independent Director | 3.9yrs | Veri yok | Veri yok | |
| Independent Other External Director | no data | Veri yok | 0.010% € 179.1k | |
| Independent Director | 3yrs | Veri yok | Veri yok |
Deneyimli Yönetim Kurulu: PHM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.9 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/11 17:52 |
| Gün Sonu Hisse Fiyatı | 2026/05/11 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Pharma Mar, S.A. 12 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Jaime Escribano | Banco Santander |
| Patricia Cifuentes | Bestinver Sociedad De Valores, S.A |
| Kambiz Yazdi | BTIG |